Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1 (original) (raw)

Abstract

Atherosclerosis and postangioplasty restenosis may result from abnormal wound healing. The present studies report that normal human smooth muscle cells are growth inhibited by TGF-beta1, a potent wound healing agent, and show little induction of collagen synthesis to TGF-beta1, yet cells grown from human vascular lesions are growth stimulated by TGF-beta1 and markedly increase collagen synthesis. Both cell types increase plasminogen activator inhibitor-1 production, switch actin phenotypes in response to TGF-beta1, and produce similar levels of TGF-beta activity. Membrane cross-linking of 125I-TGF-beta1 indicates that normal human smooth muscle cells express type I, II, and III receptors. The type II receptor is strikingly decreased in lesion cells, with little change in the type I or III receptors. RT-PCR confirmed that the type II TGF-beta1 receptor mRNA is reduced in lesion cells. Transfection of the type II receptor into lesion cells restores the growth inhibitory response to TGF-beta1, implying that signaling remains responsive. Because TGF-beta1 is overexpressed in fibroproliferative vascular lesions, receptor-variant cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components. This TGF-beta1 receptor dysfunction may be relevant for atherosclerosis, restenosis and related fibroproliferative diseases.

2667

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assoian R. K., Sporn M. B. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol. 1986 Apr;102(4):1217–1223. doi: 10.1083/jcb.102.4.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb. 1991 Jul-Aug;11(4):892–902. [PubMed] [Google Scholar]
  3. Border W. A., Noble N. A. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 Nov 10;331(19):1286–1292. doi: 10.1056/NEJM199411103311907. [DOI] [PubMed] [Google Scholar]
  4. Chan P., Patel M., Betteridge L., Munro E., Schachter M., Wolfe J., Sever P. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet. 1993 Feb 6;341(8841):341–342. doi: 10.1016/0140-6736(93)90139-8. [DOI] [PubMed] [Google Scholar]
  5. Chen R. H., Ebner R., Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science. 1993 May 28;260(5112):1335–1338. doi: 10.1126/science.8388126. [DOI] [PubMed] [Google Scholar]
  6. Dartsch P. C., Voisard R., Bauriedel G., Höfling B., Betz E. Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions. Arteriosclerosis. 1990 Jan-Feb;10(1):62–75. doi: 10.1161/01.atv.10.1.62. [DOI] [PubMed] [Google Scholar]
  7. Derynck R., Jarrett J. A., Chen E. Y., Eaton D. H., Bell J. R., Assoian R. K., Roberts A. B., Sporn M. B., Goeddel D. V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985 Aug 22;316(6030):701–705. doi: 10.1038/316701a0. [DOI] [PubMed] [Google Scholar]
  8. Derynck R., Rhee L., Chen E. Y., Van Tilburg A. Intron-exon structure of the human transforming growth factor-beta precursor gene. Nucleic Acids Res. 1987 Apr 10;15(7):3188–3189. doi: 10.1093/nar/15.7.3188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edwards D. R., Murphy G., Reynolds J. J., Whitham S. E., Docherty A. J., Angel P., Heath J. K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987 Jul;6(7):1899–1904. doi: 10.1002/j.1460-2075.1987.tb02449.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Falcone D. J., McCaffrey T. A., Haimovitz-Friedman A., Garcia M. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J Cell Physiol. 1993 Jun;155(3):595–605. doi: 10.1002/jcp.1041550317. [DOI] [PubMed] [Google Scholar]
  11. Franzén P., Ichijo H., Miyazono K. Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res. 1993 Jul;207(1):1–7. doi: 10.1006/excr.1993.1156. [DOI] [PubMed] [Google Scholar]
  12. Franzén P., ten Dijke P., Ichijo H., Yamashita H., Schulz P., Heldin C. H., Miyazono K. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell. 1993 Nov 19;75(4):681–692. doi: 10.1016/0092-8674(93)90489-d. [DOI] [PubMed] [Google Scholar]
  13. Goodman L. V., Majack R. A. Vascular smooth muscle cells express distinct transforming growth factor-beta receptor phenotypes as a function of cell density in culture. J Biol Chem. 1989 Mar 25;264(9):5241–5244. [PubMed] [Google Scholar]
  14. Grainger D. J., Witchell C. M., Watson J. V., Metcalfe J. C., Weissberg P. L. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. Cardiovasc Res. 1993 Dec;27(12):2238–2247. doi: 10.1093/cvr/27.12.2238. [DOI] [PubMed] [Google Scholar]
  15. Hariri R. J., Alonso D. R., Hajjar D. P., Coletti D., Weksler M. E. Aging and arteriosclerosis. I. Development of myointimal hyperplasia after endothelial injury. J Exp Med. 1986 Oct 1;164(4):1171–1178. doi: 10.1084/jem.164.4.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Janat M. F., Liau G. Transforming growth factor beta 1 is a powerful modulator of platelet-derived growth factor action in vascular smooth muscle cells. J Cell Physiol. 1992 Feb;150(2):232–242. doi: 10.1002/jcp.1041500203. [DOI] [PubMed] [Google Scholar]
  17. Keeton M. R., Curriden S. A., van Zonneveld A. J., Loskutoff D. J. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem. 1991 Dec 5;266(34):23048–23052. [PubMed] [Google Scholar]
  18. Kirschenlohr H. L., Metcalfe J. C., Weissberg P. L., Grainger D. J. Adult human aortic smooth muscle cells in culture produce active TGF-beta. Am J Physiol. 1993 Aug;265(2 Pt 1):C571–C576. doi: 10.1152/ajpcell.1993.265.2.C571. [DOI] [PubMed] [Google Scholar]
  19. Laiho M., Saksela O., Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem. 1987 Dec 25;262(36):17467–17474. [PubMed] [Google Scholar]
  20. Liau G., Chan L. M. Regulation of extracellular matrix RNA levels in cultured smooth muscle cells. Relationship to cellular quiescence. J Biol Chem. 1989 Jun 15;264(17):10315–10320. [PubMed] [Google Scholar]
  21. Lin H. Y., Wang X. F., Ng-Eaton E., Weinberg R. A., Lodish H. F. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell. 1992 Feb 21;68(4):775–785. doi: 10.1016/0092-8674(92)90152-3. [DOI] [PubMed] [Google Scholar]
  22. MacLeod D. C., Strauss B. H., de Jong M., Escaned J., Umans V. A., van Suylen R. J., Verkerk A., de Feyter P. J., Serruys P. W. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 1994 Jan;23(1):59–65. doi: 10.1016/0735-1097(94)90502-9. [DOI] [PubMed] [Google Scholar]
  23. Madri J. A., Bell L., Merwin J. R. Modulation of vascular cell behavior by transforming growth factors beta. Mol Reprod Dev. 1992 Jun;32(2):121–126. doi: 10.1002/mrd.1080320207. [DOI] [PubMed] [Google Scholar]
  24. Majesky M. W., Lindner V., Twardzik D. R., Schwartz S. M., Reidy M. A. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991 Sep;88(3):904–910. doi: 10.1172/JCI115393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R. S., Zborowska E., Kinzler K. W., Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995 Jun 2;268(5215):1336–1338. doi: 10.1126/science.7761852. [DOI] [PubMed] [Google Scholar]
  26. McCaffrey T. A., Falcone D. J., Brayton C. F., Agarwal L. A., Welt F. G., Weksler B. B. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol. 1989 Jul;109(1):441–448. doi: 10.1083/jcb.109.1.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McCaffrey T. A., Falcone D. J., Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol. 1992 Aug;152(2):430–440. doi: 10.1002/jcp.1041520226. [DOI] [PubMed] [Google Scholar]
  28. McCaffrey T. A., Falcone D. J. Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cells. Mol Biol Cell. 1993 Mar;4(3):315–322. doi: 10.1091/mbc.4.3.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. McCaffrey T. A., Falcone D. J., Vicente D., Du B., Consigli S., Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol. 1994 Apr;159(1):51–59. doi: 10.1002/jcp.1041590108. [DOI] [PubMed] [Google Scholar]
  30. McCaffrey T. A., Pomerantz K. B., Sanborn T. A., Spokojny A. M., Du B., Park M. H., Folk J. E., Lamberg A., Kivirikko K. I., Falcone D. J. Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries. J Clin Invest. 1995 Feb;95(2):446–455. doi: 10.1172/JCI117684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Missero C., Filvaroff E., Dotto G. P. Induction of transforming growth factor beta 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3489–3493. doi: 10.1073/pnas.88.8.3489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mulder K. M., Ramey M. K., Hoosein N. M., Levine A. E., Hinshaw X. H., Brattain D. E., Brattain M. G. Characterization of transforming growth factor-beta-resistant subclones isolated from a transforming growth factor-beta-sensitive human colon carcinoma cell line. Cancer Res. 1988 Dec 15;48(24 Pt 1):7120–7125. [PubMed] [Google Scholar]
  33. Mustoe T. A., Pierce G. F., Thomason A., Gramates P., Sporn M. B., Deuel T. F. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 1987 Sep 11;237(4820):1333–1336. doi: 10.1126/science.2442813. [DOI] [PubMed] [Google Scholar]
  34. Nabel E. G., Shum L., Pompili V. J., Yang Z. Y., San H., Shu H. B., Liptay S., Gold L., Gordon D., Derynck R. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10759–10763. doi: 10.1073/pnas.90.22.10759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nikol S., Isner J. M., Pickering J. G., Kearney M., Leclerc G., Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992 Oct;90(4):1582–1592. doi: 10.1172/JCI116027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. O'Brien E. R., Alpers C. E., Stewart D. K., Ferguson M., Tran N., Gordon D., Benditt E. P., Hinohara T., Simpson J. B., Schwartz S. M. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ Res. 1993 Aug;73(2):223–231. doi: 10.1161/01.res.73.2.223. [DOI] [PubMed] [Google Scholar]
  37. Overall C. M., Wrana J. L., Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem. 1989 Jan 25;264(3):1860–1869. [PubMed] [Google Scholar]
  38. Pietenpol J. A., Stein R. W., Moran E., Yaciuk P., Schlegel R., Lyons R. M., Pittelkow M. R., Münger K., Howley P. M., Moses H. L. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell. 1990 Jun 1;61(5):777–785. doi: 10.1016/0092-8674(90)90188-k. [DOI] [PubMed] [Google Scholar]
  39. Raghow R., Postlethwaite A. E., Keski-Oja J., Moses H. L., Kang A. H. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest. 1987 Apr;79(4):1285–1288. doi: 10.1172/JCI112950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Raghow R. Role of transforming growth factor-beta in repair and fibrosis. Chest. 1991 Mar;99(3 Suppl):61S–65S. doi: 10.1378/chest.99.3_supplement.61s. [DOI] [PubMed] [Google Scholar]
  41. Reddy K. B., Howe P. H. Transforming growth factor beta 1-mediated inhibition of smooth muscle cell proliferation is associated with a late G1 cell cycle arrest. J Cell Physiol. 1993 Jul;156(1):48–55. doi: 10.1002/jcp.1041560108. [DOI] [PubMed] [Google Scholar]
  42. Reiss M., Vellucci V. F., Zhou Z. L. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. Cancer Res. 1993 Feb 15;53(4):899–904. [PubMed] [Google Scholar]
  43. Ross R., Masuda J., Raines E. W., Gown A. M., Katsuda S., Sasahara M., Malden L. T., Masuko H., Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990 May 25;248(4958):1009–1012. doi: 10.1126/science.2343305. [DOI] [PubMed] [Google Scholar]
  44. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  45. Rossi P., Karsenty G., Roberts A. B., Roche N. S., Sporn M. B., de Crombrugghe B. A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-beta. Cell. 1988 Feb 12;52(3):405–414. doi: 10.1016/s0092-8674(88)80033-3. [DOI] [PubMed] [Google Scholar]
  46. Sarzani R., Brecher P., Chobanian A. V. Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest. 1989 Apr;83(4):1404–1408. doi: 10.1172/JCI114029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sato Y., Tsuboi R., Lyons R., Moses H., Rifkin D. B. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol. 1990 Aug;111(2):757–763. doi: 10.1083/jcb.111.2.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Shi D. L., Savona C., Chambaz E. M., Feige J. J. Stimulation of fibronectin production by TGF-beta 1 is independent of effects on cell proliferation: the example of bovine adrenocortical cells. J Cell Physiol. 1990 Oct;145(1):60–68. doi: 10.1002/jcp.1041450110. [DOI] [PubMed] [Google Scholar]
  49. Speir E., Modali R., Huang E. S., Leon M. B., Shawl F., Finkel T., Epstein S. E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994 Jul 15;265(5170):391–394. doi: 10.1126/science.8023160. [DOI] [PubMed] [Google Scholar]
  50. Stemerman M. B., Weinstein R., Rowe J. W., Maciag T., Fuhro R., Gardner R. Vascular smooth muscle cell growth kinetics in vivo in aged rats. Proc Natl Acad Sci U S A. 1982 Jun;79(12):3863–3866. doi: 10.1073/pnas.79.12.3863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wolf Y. G., Rasmussen L. M., Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest. 1994 Mar;93(3):1172–1178. doi: 10.1172/JCI117070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wrana J. L., Attisano L., Wieser R., Ventura F., Massagué J. Mechanism of activation of the TGF-beta receptor. Nature. 1994 Aug 4;370(6488):341–347. doi: 10.1038/370341a0. [DOI] [PubMed] [Google Scholar]